跳至主要内容
临床试验/NCT00316654
NCT00316654已完成4 期

A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule

Novartis Vaccines2 个研究点 分布在 2 个国家目标入组 489 人开始时间: 2005年2月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
489
试验地点
2
主要终点
Immunogenicity: serum antibody responses, as measured by bactericidal activity,using hBCA

研究概览

简要总结

Persistence of Antibody Response to N. meningitidis Group C in Children

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
7 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • healthy children

排除标准

  • previous ascertained or suspected disease caused by N. meningitidis
  • previous significant acute or chronic infections
  • any other serious disease

结局指标

主要结局

Immunogenicity: serum antibody responses, as measured by bactericidal activity,using hBCA

次要结局

  • Evaluate and compare persistence of antibody response to N. meningitidis serogroup C as measured by serum bactericidal activity
  • safety and tolerability

研究者

发起方
Novartis Vaccines
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验